Continuous Manufacture in the Broader Context of Sustainable Supply of Medicines

Flow Chemistry, Continuous Manufacture has been divisive topic in Industry; some believe it is the future, others a distraction. I think Continuous Manufacture only makes sense when viewed as part of some broader socio-economics changes – the need to supply medicines reliably, affordably and without creating harm (environment/safety). In this talk I will use my journey starting with Petrochemical Manufacture to building some of the first pharmaceutical multistage API processes to illustrate why Continuous Manufacture matters – but only as part of some broader changes: namely automation, modularisation and digitalisation that support changing the current supply regime.

Biography

Andrew Rutter is an independent consultant with expertise in the application of Advanced Manufacturing Technologies, particularly in Medicine Manufacture. A Chemical Engineer by training he spent 20 years developing new processes API for GSK, including appointment, as EFPIA representative, to the Expert Working Group for ICH Q13. Prior to this he worked on Large Scale Petrochemical processes, and Process Economics for IBM. He currently advises many major Pharma companies, and Government organisations.